Get the Stockscreener App
1.06
4.50%
-0.05
Pre-market:
1.09
0.03
+2.83%
Immuron Limited Adr stock is traded at $1.06, with a volume of 36,149.
It is down -4.50% in the last 24 hours and down -3.64% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
See More
Previous Close:
$1.11
Open:
$1.12
24h Volume:
36,149
Relative Volume:
0.19
Market Cap:
$8.56M
Revenue:
$4.83M
Net Income/Loss:
$-2.99M
P/E Ratio:
-2.2065
EPS:
-0.4804
Net Cash Flow:
$-2.83M
1W Performance:
-6.19%
1M Performance:
-3.64%
6M Performance:
+11.32%
1Y Performance:
-38.37%
1-Day Range:
$1.06
$1.1202
1-Week Range:
$1.06
$1.2299
52-Week Range:
$0.6765
$2.39
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.06 | 8.56M | 4.83M | -2.99M | -2.83M | -0.4804 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immuron Limited Adr Stock (IMRN) Latest News
Immuron Limited Sponsored ADR Revenue Breakdown – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Revenue Breakdown – LSX:A2DTD8 - TradingView
Immuron Limited (NASDAQ: IMRN) grows FY26 revenue to A$7.7m - Stock Titan
Immuron FY26 SalesFour Consecutive Quarters of Growth over Prior Year - Sahm
BNY Mellon Lifts Substantial Holding in Immuron to 44.61% via ADR Program Deposits - Kalkine
Immuron (NASDAQ: IMRN) lifts FY26 Travelan sales 6% to AUD$7.7m - Stock Titan
BNY Mellon Boosts Immuron Stake to 44.61% Through ADR Share Deposits by July 2026 - Kalkine Media
Immuron (NASDAQ: IMRN) advances IMM-529 CDI drug with new partnering push - Stock Titan
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewswire Inc.
IMRNImmuron Limited ADR Revenue Breakdown - Finviz
A2DTD8 Forecast — Price Target — Prediction for 2027 - TradingView
ANWA Forecast — Price Target — Prediction for 2027 - TradingView
Immuron (NASDAQ: IMRN) now has 322.8M ordinary shares on issue - Stock Titan
Price to earnings forward of Immuron Limited Sponsored ADR – MUN:ANWA - TradingView
Immuron Limited Sponsored ADR Actuals & Estimates (NASDAQ:IMRN) - TradingView
Form 6K Immuron Ltd ADR For: 23 June By Investing.com - Investing.com South Africa
Form 6K Immuron Ltd ADR For: 23 June - Investing.com UK
Immuron (NASDAQ: IMRN) cancels 3.8M shares in small holder buy-back - Stock Titan
Immuron (NASDAQ: IMRN) reports expiry of 1.43M options and updated capital - Stock Titan
Which stocks have an unusual volume on Thursday? - ChartMill
Immuron (NASDAQ: IMRN) responds to ASX query on share price - Stock Titan
Wondering what's happening in today's after-hours session? - ChartMill
Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3 - Stock Titan
Number of shareholders of Immuron Limited Sponsored ADR – LSX:A2DTD8 - TradingView
Immuron (NASDAQ: IMRN) details TD portfolio growth and partnering push - Stock Titan
Immuron (IMRN) chairman discloses 1.67M share options - Stock Titan
Immuron (NASDAQ: IMRN) CEO schedules Emerging Growth Conference presentation - Stock Titan
Unusual VolumeStock ScreenerNews - Finviz
IMRN Stock Price, Quote & Chart | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron Double Digit 3Q Sales Growth - Sahm
Top 10 at 11: Wall Street hits all-time highs but ASX opens lower as banks retreat - MSN
Immuron (NASDAQ: IMRN) lifts Travelan sales with strong Canada Q3 surge - Stock Titan
Immuron (NASDAQ: IMRN) offers cost-free sale facility for small shareholdings - Stock Titan
Operating cash flow per share of Immuron Limited Sponsored ADR – GETTEX:ANWA - TradingView
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Democrat and Chronicle
IMRN Earnings History & Surprises | EPS & Revenue Results | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Sahm
Immuron (NASDAQ: IMRN) boosts cash, pursues partners for IMM-124E and IMM-529 - Stock Titan
Immuron Reports HY26 Results and Strategic Reset - ChartMill
Immuron (NASDAQ: IMRN) gains A$1.12M non-dilutive R&D refund - Stock Titan
Immuron (NASDAQ: IMRN) shareholders back ratification of prior share issues - Stock Titan
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - USA Today
Immuron Reports Continued Sales Growth - Finviz
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):